Accelr8's Stock Plummets after BD Declines Option on Bacterial Dx Tech

BD advised the company that it would decline an exclusive license option for the technology associated with an 18-month testing agreement it inked with Accelr8 in April 2008.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories